publication date: May. 8, 2015

Nascent Group Points to a Way To Validate, Pay for Genomic Tests



How is this for a plan:

Replace the U.S. system for validation and payment for cancer genomic tests with something that actually makes sense.

Dane Dickson, a doctor in Idaho, who until recently had the distinction of being the only oncologist working under the roof of Centers for Medicare and Medicaid Services, would like to do just that—and some important players in cancer research are betting on his success.

Until recently, Dickson, who is 46, was setting cancer policy as a part-time employee of at Palmetto GBA, a CMS contractor which has pioneered a program for approval of genomic tests (The Cancer Letter, Jan. 23). This was an important position since Palmetto’s MolDX program is likely to shape payment policy for the entire Medicare program.

Now, Dickson has struck out on his own, launching a nonprofit public-private partnership called MED-C, short for Medical Evidence Development Consortium, which aims to set policy on validation of genomic tests.

In his former job at CMS, Dickson had his finger on the pulse of the genomic industry:

“I could see a very disturbing trend, namely the end of personalized medicine before it could ever get started. I saw new technology with great promise, but very little direct application to patients,” Dickson said in a conversation with The Cancer Letter. “I saw the … Continue reading 41-18 Nascent Group Points to a Way To Validate, Pay for Genomic Tests

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.